|
|
|
| Clinical Evaluation of Using Recombinant Human Interleukin 11 for Malignant Tumor Patients after Chemotherapy Induced Severe Thrombocytopenia |
| General Hospital of Fushun Mining Bureau， Fushun 113008，China |
|
|
|
Abstract Objective：To evaluate the preventive and curative effects of recombinant human interleukin 11 （rhIL-11） for malignant tumor patients after chemotherapy induced severe thrombocytopenia.Method：58 patients with malignant tumor after chemotherapy induced severe thrombocytopenia were enrolled in the study， in the presence of severe thrombocytopenia after treated were given rhIL-11（ as treatment period）; all the patients in the next cycle of chemotherapy at 48 h after administration were given rhIL-11 preventive treatment（ as prevention and treatment period）. The 2 cycle degree of thrombocytopenia and duration were observed by using own control methods.Result：The effective rate of treatment period was 100%（58/58）;the treatment period and the prevention in treatment period on medication duration was respectively（10.9±5.7）d and（ 5.3±3.8）d;thrombocytopenia duration was respectively（11.6±5.8）d and（5.2±3.9）d; platelet minimum were respectively（25.9±15.7）×109/L and（42.3±18.8）×109/L， the differences were statistically significant（P<0.05）.The incidence rate of adverse reaction in treatment period was 29.3%（17/58），and in prevention treatment period was 25.9%（ 15/58），the difference was not statistically significant. Conclusion：RhIL-11 can promote the recovery of patients with malignant tumor chemotherapy induced severe thrombocytopenia，reduce the incidence of severe thrombocytopenia，and shorten the duration of severe thrombocytopenia
with mild adverse reaction， also the patients can tolerate.
|
|
|
|
|
|
|
|
|
